Stock Watch: Sanofi Basks While Novartis Falters As Their Biggest Products’ Fates Diverge
Investors Applaud Dupixent’s Q3 Growth While Entresto’s Expiry Starts
• By Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS 
